Abstract
The use of highly immunosuppressive therapies prior to and after transplantation and the use of matched unrelated (MUD) and mismatched related (MRD) donors have increased the incidence of CMV infection and disease. Methods: Twenty-four (24) out of 50 patients have been enrolled into a prospective trial evaluating the safety and efficacy of valganciclovir for the early prophylaxis of CMV infection. Patients are either CMV seropositive or CMV seronegative receiving CMV seropositive stem cell products.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.